Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. lowered its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 6.5% in the second quarter, HoldingsChannel reports. The firm owned 2,317 shares of the biotechnology company’s stock after selling 162 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Ascendis Pharma A/S were worth $316,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. Gilbert & Cook Inc. boosted its position in Ascendis Pharma A/S by 8.4% in the 4th quarter. Gilbert & Cook Inc. now owns 2,838 shares of the biotechnology company’s stock valued at $357,000 after buying an additional 220 shares during the period. Quadrant Capital Group LLC boosted its holdings in Ascendis Pharma A/S by 90.4% in the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 151 shares during the period. PNC Financial Services Group Inc. increased its holdings in Ascendis Pharma A/S by 1.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 16,384 shares of the biotechnology company’s stock worth $2,064,000 after purchasing an additional 159 shares during the period. Trexquant Investment LP acquired a new stake in Ascendis Pharma A/S in the 4th quarter valued at about $1,243,000. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of Ascendis Pharma A/S by 37.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 91 shares during the period.

Analyst Upgrades and Downgrades

ASND has been the topic of several analyst reports. Stifel Nicolaus began coverage on shares of Ascendis Pharma A/S in a report on Friday, May 31st. They issued a “buy” rating and a $200.00 target price on the stock. Jefferies Financial Group raised their price objective on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a report on Tuesday, August 13th. JPMorgan Chase & Co. lowered their target price on shares of Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating for the company in a research note on Wednesday, September 4th. The Goldman Sachs Group raised their price target on Ascendis Pharma A/S from $170.00 to $195.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th. Finally, Citigroup lowered their price objective on Ascendis Pharma A/S from $193.00 to $178.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $187.08.

Ascendis Pharma A/S Stock Up 17.1 %

NASDAQ:ASND opened at $139.57 on Tuesday. Ascendis Pharma A/S has a 52-week low of $85.29 and a 52-week high of $161.00. The stock’s 50 day moving average price is $132.51 and its 200 day moving average price is $136.47. The company has a market capitalization of $8.13 billion, a PE ratio of -14.52 and a beta of 0.63.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.